SERA 3.19 (+1.92%)
US81749D1072Medical Diagnostics & ResearchDiagnostics & Research

Sera Prognostics (SERA) Competitor Comparison

We are evaluating the key criteria listed to compare Sera Prognostics (SERA) against its competitors in the Diagnostics & Research industry.

Performance 10 years - SERA ranking 42 / 58

These are the competitors of Sera Prognostics in the industry Diagnostics & Research ranked by performance 10 years
1. Heska HSKA
1.65K
2. Lantheus Holdings LNTH
1.39K
3. Medpace Holdings MEDP
919.93
4. Natera NTRA
643.72
5. RadNet RDNT
466.28
6. IDEXX Laboratories IDXX
417.52
7. DexCom DXCM
284.02
8. PerkinElmer PKI
247.07
9. Thermo Fisher Scientific TMO
230.6
10. Danaher DHR
222.8
11. Mettler-Toledo MTD
219.29
12. CareDx CDNA
216.48
13. Twist Bioscience TWST
178.38
14. Waters WAT
162.94
15. Agilent Technologies A
147.12
16. IQVIA Holdings IQV
134.55
17. Icon ICLR
120.01
18. Quest Diagnostics DGX
118.56
19. Syneos Health SYNH
113.83
20. Laboratory Corp of America Holdings LH
110.81
21. Exact Sciences EXAS
98.37
22. Fulgent Genetics FLGT
83.06
23. NeoGenomics NEO
82.54
24. Charles River Laboratories CRL
76.65
25. Meridian Bioscience VIVO
60.69
26. Guardant Health GH
46.23
27. Qiagen QGEN
45.77
28. Inotiv NOTV
14.63
29. Ortho Clinical Diagnostics Holdings OCDX
13.74
30. National Research NRC
-12.12
31. Olink Holding OLK
-26.82
32. Anixa Biosciences ANIX
-36.75
33. Bioventus BVS
-44.83
34. Neogen NEOG
-54.86
35. Illumina ILMN
-57.95
36. Sotera Health SHC
-61.7
37. Global Cord Blood CO
-66.57
38. DarioHealth DRIO
-75.47
39. Exagen XGN
-76.01
40. Myriad Genetics MYGN
-76.83
41. Enzo Biochem ENZ
-77.8
42. Sera Prognostics SERA
-78.75
43. Pacific Biosciences of California PACB
-78.83
44. Co-Diagnostics CODX
-83.5
45. MaxCyte MXCT
-85.58
46. Psychemedics PMD
-85.89
47. Personalis PSNL
-86.82
48. MDxHealth MDXH
-87.82
49. bioAffinity Technologies BIAF
-88.45
50. Biodesix BDSX
-92.64
51. SeqLL SQL
-95.22
52. Prenetics Global PRE
-96.85
53. Neuronetics STIM
-97
54. Aspira Womens Health AWH
-97.44
55. Trinity Biotech TRIB
-98.9
56. Organovo Holdings ONVO
-99.26
57. Interpace Biosciences IDXG
-99.49
58. Precipio PRPO
-99.8

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.